Cohen Cheryl 4

What Happened

• Cheryl Cohen, a director of ImmunityBio, exercised 55,979 options (code M) at $2.98 per share (cost $166,817) and separately sold 131,210 shares in an open‑market transaction (code S) on July 2, 2026. The open‑market sales generated about $1,246,941 (weighted average sale price reported in the $9.50–$9.52 range; aggregate reported as $9.50).
• The filing also records a disposition of the related derivative instrument for 55,979 shares at $0.00 (typical when an option is converted to shares). The sale was executed under a Rule 10b5‑1 trading plan entered into by Ms. Cohen on February 27, 2026 — a prearranged plan that automates trades.

Key Details

• Transaction date: July 2, 2026. Form 4 filed July 6, 2026 (appears timely).
• Options exercised: 55,979 shares at $2.98 each; cash paid ≈ $166,817.
• Open‑market sale: 131,210 shares; weighted average sale price reported $9.50–$9.52 (aggregate ~$1,246,941).
• Derivative disposition: 55,979 instruments disposed at $0.00 (reflects conversion on exercise).
• Footnotes: Sale effected pursuant to a 10b5‑1 plan (entered Feb 27, 2026). Reporting person can provide per‑price breakdown on request.
• Shares owned after the transactions: not specified in this Form 4.

Context

• Code meanings: M = exercise/conversion of derivative (options); S = sale. Here, Ms. Cohen exercised options and sold shares in the open market; the filing structure is consistent with an exercise plus sale under a prearranged 10b5‑1 plan.
• For retail investors: exercises followed by immediate sales are generally routine (often to cover option costs or diversify) and the 10b5‑1 disclosure indicates the sale was preplanned rather than opportunistic. This filing is factual and does not by itself indicate management’s view of company prospects.